REPL
The FDA said “not enough” — twice
Replimune just took a gut punch from the FDA: its RP1 melanoma therapy was rejected again after regulators said the data still didn’t prove effectiveness strongly enough. That’s a brutal sequel nobody wanted, especially after the agency had already raised similar concerns last July.
Why the stock is getting crushed
The market did what the market does when a biotech’s lead asset gets shoved back by regulators: it hit the sell button first and asked questions later. Shares were down about 60% premarket and looked headed for fresh lows, while JPMorgan cut the stock to Underweight and Jefferies basically waved a yellow flag saying the road ahead looks rough.
The part investors should actually care about
This isn’t just a one-day headline. RP1 was the company’s main shot at turning clinical hope into a commercial business, and now Replimune is staring at a much longer timeline — or maybe a dead end if it can’t convince the FDA on a resubmission.
Management also hinted at belt-tightening, saying it may cut jobs and scale back operations. Translation: when the science gets a red light, the payroll often does too.
Big picture: In biotech, a regulatory rejection can be the difference between “growth story” and “survival mode.” Right now, REPL is very much in the latter camp.